Core Insights - The expert consensus on the prevention and treatment of vascular diseases and their target organ damage has been officially released, with the core product of Wuzhou Pharmaceutical, an affiliate of Zhongheng Group, namely the injectable Thrombus-Resolving Agent (freeze-dried), being included as a recommended medication for "activating blood circulation and removing blood stasis" [1][2] - The injectable Thrombus-Resolving Agent received the highest level of evidence (Ia) and an A-level recommendation, establishing it as a significant choice in the field of traditional Chinese medicine for multi-target organ protection against vascular diseases [1] Industry and Company Summary - The expert consensus was guided by academicians Ge Junbo and Chen Keji, involving 43 authoritative experts from 19 provinces, covering key areas of vascular diseases such as cardiovascular, cerebrovascular, renal, ocular, peripheral vascular, and endocrine [1] - The injectable Thrombus-Resolving Agent's clinical value is highlighted by its indications, which include coronary heart disease angina, myocardial infarction, cerebral infarction, retinal vein occlusion, and deep vein thrombosis of the lower limbs, addressing the treatment needs of multiple target organs [1][2] - The inclusion of the injectable Thrombus-Resolving Agent in the expert consensus not only recognizes its clinical efficacy but also marks a significant step in Wuzhou Pharmaceutical's academic positioning in the field of vascular disease treatment, reinforcing its industry status in traditional Chinese medicine [2]

Core Viewpoint - Guangxi Wuzhou Zhongheng Group Co., Ltd. has successfully transformed from a traditional pharmaceutical company to a technology-driven enterprise during the "14th Five-Year Plan" period, focusing on innovation and research and development in traditional Chinese medicine and chemical drugs [1][2]. Innovation in Pharmaceuticals - Zhongheng Group has made significant strides in innovative drugs, particularly with the "Sanqi Granules," which received clinical trial approval from the National Medical Products Administration, targeting chronic kidney disease [2][3]. - The market for chronic kidney disease in China is substantial, with approximately 150 million patients and a market size exceeding 32 billion yuan, indicating a significant opportunity for the company [2]. Product Development and Brand Value - The company has been actively involved in the secondary development of core products, with the "Zhonghua Die Da Wan" being recognized as one of the "China's 500 Most Valuable Brands," valued at over 10 billion yuan [3]. - Zhongheng Group is expanding into cardiovascular disease treatments, with a new innovative drug targeting chronic heart failure, addressing a market with over 12 million patients in China [3]. Research and Development Investment - From 2021 to 2024, Zhongheng Group invested nearly 687 million yuan in R&D, accounting for 6.11% of its revenue, establishing a robust research funding mechanism [5]. - The company has formed partnerships with national key laboratories and universities to enhance its research capabilities and facilitate the transition from research to industry [5]. Smart Manufacturing and Technology Integration - Zhongheng Group has integrated modern technology into its manufacturing processes, significantly improving production efficiency, with the solid preparation workshop achieving a production rate of 1,000 pills per minute [6]. - The company holds 343 valid patents and has received multiple awards for its innovations, showcasing its commitment to modernizing traditional practices [6]. Brand Expansion and Market Reach - The company has successfully modernized its product offerings, such as the "Guilinggao," which has evolved from a traditional dessert to a health food product, now available in various convenient packaging [7][8]. - Zhongheng Group's brands have entered high-end retail markets and expanded online, contributing to a combined brand value exceeding 40 billion yuan during the "14th Five-Year Plan" [9].

Core Viewpoint - The report highlights the financial performance and operational strategies of Guangxi Wuzhou Zhongheng Group Co., Ltd. for the first half of 2025, emphasizing growth in net profit and strategic initiatives in the pharmaceutical and health sectors [1][2]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.45 billion yuan, representing a 2.84% increase compared to the same period last year [2]. - The total profit decreased by 19.38% to approximately 27.73 million yuan, while the net profit attributable to shareholders increased by 23.59% to approximately 27.08 million yuan [2]. - The net cash flow from operating activities showed a significant decline of 132.23%, amounting to approximately -69.18 million yuan [2]. - As of June 30, 2025, the total assets reached approximately 11.03 billion yuan, a slight increase of 0.49% from the end of the previous year [2]. Business Operations - Zhongheng Group focuses on pharmaceutical manufacturing, with nine key subsidiaries, including Wuzhou Pharmaceutical, which specializes in traditional Chinese medicine [3][4]. - The company aims to enhance the quality of life through its mission of "producing quality Chinese medicine to protect public health" [3][4]. - Wuzhou Pharmaceutical has a rich history and is recognized as a leading enterprise in the production of traditional Chinese medicine, holding numerous production approvals and patents [3][4]. Industry Context - The pharmaceutical manufacturing industry in China faced challenges in the first half of 2025, with a slight decline in revenue and profit among large-scale enterprises [9]. - The aging population in China is expected to drive demand for healthcare products, with projections indicating that the population aged 65 and above will reach 220 million by the end of 2024 [9]. - The industry is undergoing structural changes, with a focus on innovation and international expansion as key growth drivers [10]. Strategic Initiatives - The company is actively pursuing innovation in drug development and has established a comprehensive research and development framework to support new product launches [17]. - Zhongheng Group is enhancing its marketing strategies and expanding its distribution channels to improve market penetration and sales performance [16][17]. - The company has implemented a three-pronged development strategy focusing on sales-driven revenue growth, investment optimization, and strengthening research capabilities [14][15].

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-18 广西梧州中恒集团股份有限公司 关于控股子公司参加全国中成药采购联盟集中带量 采购非报价代表品拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）的控 股子公司广西梧州制药（集团）股份有限公司（以下简称"梧州制药"）参加了 全国中成药采购联盟集中带量采购工作。近日，根据全国中成药联合采购办公室 发布的《全国中成药采购联盟集中采购复活拟中选及非报价代表品拟中选结果公 示》，梧州制药产品注射用血栓通（冻干）非报价代表品拟中选本次全国中成药 采购联盟集中带量采购，现将相关情况公告如下： 注：1.该产品的拟中选价格、拟中选数量及拟供应省区均以联采办发布的最终数据为准； 2.在全国中成药采购联盟集中带量采购工作中，梧州制药的报价代表品为注射用血栓通 （冻干）（规格 150mg/支），其拟中选详情请查阅公司于 2025 年 1 月 2 日在上海证券交易 所网站（www.sse.com.cn）披露的 ...